This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): pilocarpine hydrochloride
Description: Salagen Tablets are prescribed for the relief of dry mouth (xerostomia) symptoms caused by Sjogren's syndrome or radiation therapy. The active ingredient of Salagen, pilocarpine, is a cholinergic parasympathomimetic agent that activates the muscarinic acetylcholine receptor. It exerts a broad spectrum of pharmacologic effects including increased secretion by the exocrine glands such as the salivary glands.
Deal Structure: Salagen was originally developed by MGI Pharma.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
Partners: Kissei Pharmaceutical Co., Ltd
Pink Sheet In Brief: MGI Salagen
Additional information available to subscribers only: